Camlin Fine Sciences · NSE: CAMLINFINE · BSE: 532834

Q4 FY22 results · Jan–Mar 2022

Camlin Fine Sciences reported revenue from operations of ₹389.23 crore (up 19.2% from Q4 FY21) and net profit of ₹13.33 crore (down 15.2% from Q4 FY21) for Q4 FY22 (Jan–Mar 2022), on a consolidated basis.

Consolidated · ₹ crore
Item	Q4 FY22	Q4 FY21	YoY	Q3 FY22	QoQ
Revenue from operations	389.23	326.62	+19.2%	380.82	+2.2%
Other income	21.32	2.09	+918.5%	5.58	+282.0%
Total income	410.54	328.72	+24.9%	386.40	+6.2%
Profit before share of associates & JVs and tax	19.95	28.60	−30.3%	40.69	−51.0%
Share of profit/(loss) of associates & JVs	0.04	0.00		0.00
Net profit for the period	13.33	15.72	−15.2%	27.15	−50.9%
Attributable to shareholders of the company	15.13	14.27	+6.1%	—	—
EPS, basic (₹)	1.16	1.16	not comparable	2.25	not comparable
Net margin (%)	3.4	4.8		7.1

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q4 FY22	Q4 FY21	YoY	Q3 FY22	QoQ
Revenue from operations	201.39	168.46	+19.5%	200.22	+0.6%
Other income	7.56	2.78	+171.7%	7.25	+4.3%
Total income	208.95	171.24	+22.0%	207.47	+0.7%
Profit before tax	22.06	5.90	+273.9%	17.21	+28.2%
Net profit for the period	15.75	2.14	+637.5%	12.38	+27.2%
EPS, basic (₹)	1.21	0.17	not comparable	0.97	not comparable
Net margin (%)	7.8	1.3		6.2

Consolidated

Filed with BSE: 20 May 2022, 18:03 IST
Board meeting: 19 May 2022
Period: 01 Jan 2022 to 31 Mar 2022
Review status: Audited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 20 May 2022, 18:03 IST
Board meeting: 19 May 2022
Period: 01 Jan 2022 to 31 Mar 2022
Review status: Audited
Source: XBRL filing on BSE